アジア太平洋地域の腫瘍学に基づく分子診断市場規模は、2024年には8億2,250万ドルと推定されました、2033年には15億6,075万ドルに達すると予測され、2025年から2033年にかけて6.8%のCAGRで成長する見込みです。乳がん、前立腺がん、大腸がんにおける罹患率の増加と人口の高齢化が、この地域における効果的な診断ソリューションの需要を牽引しています。技術の進歩、ポイントオブケア検査（POCT）の普及、バイオマーカー同定システムの開発が市場拡大を支えています。さらに、がんスクリーニングと早期発見を目的とした政府の取り組みや、新興国における医療投資の増加も、分子診断の需要増加に寄与しています。
目次
Table of Contents
Chapter 1. Asia Pacific Oncology Based Molecular Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Product Segment
1.1.1.3. Technology segment
1.2. Country Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Asia Pacific Oncology Based Molecular Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Type and Product Snapshot
2.3. Technology Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Asia Pacific Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising Global Cancer Prevalence
3.4.2. Adoption of Precision Medicine
3.4.3. Advances in Molecular Testing Technologies
3.5. Market Restraint Analysis
3.5.1. High Costs of Testing and Equipment
3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
3.5.3. Limited Access in Low-Resource Regions
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis
4.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Movement Analysis
4.2. Breast Cancer
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Prostate Cancer
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Colorectal Cancer
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Cervical Cancer
4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Liver Cancer
4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Lung Cancer
4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Blood Cancer
4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Kidney Cancer
4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.10. Others
4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis
5.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
5.2. Instruments
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Reagents
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Others
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
6.2. PCR
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. In situ hybridization
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. INAAT
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Chips and microarrays
6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Mass spectrometry
6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Sequencing
6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. TMA
6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Others
6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Asia Pacific Oncology Based Molecular Diagnostics Market: Country Business Analysis
7.1. Country Market Snapshot
7.2. Asia Pacific
7.2.1. Asia Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.2. Japan
7.2.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. China
7.2.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. India
7.2.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.2.5. Australia
7.2.5.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.5.2. Key Country Dynamics
7.2.5.3. Regulatory Framework
7.2.5.4. Reimbursement Scenario
7.2.5.5. Competitive Scenario
7.2.6. New Zealand
7.2.6.1. New Zealand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
7.2.6.2. Key Country Dynamics
7.2.6.3. Regulatory Framework
7.2.6.4. Reimbursement Scenario
7.2.6.5. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. New Type Launch
8.2.2. Partnerships
8.2.3. Acquisiton
8.2.4. Collaboration
8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. Abbott
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Type Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Agilent Technologies, INC.
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Type Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. bioMerieux SA
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Type Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Danaher
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Type Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. F. Hoffmann-La Roche Ltd.
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Type Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. ILLUMINA
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Type Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Novartis AG
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Type Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. QIAGEN
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Type Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Siemens Healthineers AG
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Type Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. TBG Diagnostics Limited
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Type Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Thermo Fisher Scientific Inc
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Type Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Sysmex
8.5.12.1. Company Overview
8.5.12.2. Financial Performance
8.5.12.3. Type Benchmarking
8.5.12.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Asia Pacific Oncology Based Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 4 Asia Pacific Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 5 Asia Pacific Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 6 Asia Pacific Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 7 Japan Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 8 Japan Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 9 Japan Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 10 China Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 11 China Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 12 China Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 13 India Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 14 India Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 15 India Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 16 Australia Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 17 Australia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 18 Australia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 19 New Zealand Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 20 New Zealand Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 21 New Zealand Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Asia Pacific Oncology Based Molecular Diagnostics Market: Key Market Driver Analysis
Fig. 7 Asia Pacific Oncology Based Molecular Diagnostics Market: Key Market Restraint Analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Asia Pacific Oncology Based Molecular Diagnostics Market: Porter’s analysis
Fig. 10 Asia Pacific Oncology Based Molecular Diagnostics Market: PESTEL analysis
Fig. 11 Asia Pacific Oncology Based Molecular Diagnostics Market type outlook key takeaways
Fig. 12 Asia Pacific Oncology Based Molecular Diagnostics Market: Type movement analysis
Fig. 13 Breast Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 14 Prostate Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 15 Colorectal Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 16 Cervical Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 17 Liver Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 18 Lung Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 19 Blood Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 20 Kidney Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 21 Others Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 22 Asia Pacific Oncology Based Molecular Diagnostics Market product outlook key takeaways
Fig. 23 Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
Fig. 25 Reagents market estimates, 2021 - 2033 (USD Million)
Fig. 26 Others market estimates, 2021 - 2033 (USD Million)
Fig. 27 Asia Pacific Oncology Based Molecular Diagnostics Market technology outlook key takeaways
Fig. 28 Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
Fig. 29 PCR market estimates, 2021 - 2033 (USD Million)
Fig. 30 In situ hybridization market estimates, 2021 - 2033 (USD Million)
Fig. 31 INAAT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Chips and microarrays market estimates, 2021 - 2033 (USD Million)
Fig. 33 Mass spectrometry market estimates, 2021 - 2033 (USD Million)
Fig. 34 Sequencing market estimates, 2021 - 2033 (USD Million)
Fig. 35 TMA market estimates, 2021 - 2033 (USD Million)
Fig. 36 Others market estimates, 2021 - 2033 (USD Million)
Fig. 37 Country marketplace: Key takeaways
Fig. 38 Asia Pacific Oncology Based Molecular Diagnostics Market: Country movement analysis
Fig. 39 Asia Pacific oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 40 Japan oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 41 China oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 42 India oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 43 Australia oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 44 New Zealand oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 45 Strategy framework
